Related Experiment Video
Updated: May 3, 2026
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice
Tiia Koho1, Minni R L Koivunen2, Sami Oikarinen3
1BioMediTech, University of Tampere and Tampere University Hospital, Biokatu 6, FI-33014 University of Tampere, Finland.
Insights
Developing a Coxsackievirus B3 (CVB3) vaccine is crucial for preventing viral myocarditis and dilated cardiomyopathy. This study established an efficient purification method for CVB3 virus-like particles (VLPs), showing their strong potential as a vaccine candidate.
Area of Science:
- Virology
- Immunology
- Biotechnology
Background:
- Coxsackievirus B3 (CVB3) causes viral myocarditis and dilated cardiomyopathy.
- No vaccine or therapeutic agent is currently available for CVB3 infection.
- Vaccination could prevent serious or fatal CVB3-related diseases.
Purpose of the Study:
- To develop an efficient and scalable purification method for CVB3 virus-like particles (VLPs).
- To assess the vaccine potential of purified CVB3 VLPs.
Main Methods:
- Established an ion exchange chromatography-based purification system for CVB3 and CVB3 VLPs.
- Characterized purified VLPs using biophysical methods.
- Immunized mice with VLPs to evaluate immune response.
Main Results:
- Achieved efficient and scalable purification of CVB3 VLPs.
- Produced high-purity VLPs with excellent quality.
- Demonstrated a strong immune response in mice immunized with VLPs.
Conclusions:
- The developed purification method is suitable for industrial-scale vaccine production.
- CVB3 VLPs show significant promise as a vaccine candidate for preventing CVB3-related diseases.
Abstract:
Coxsackievirus B3 (CVB3) is an important cause of acute and chronic viral myocarditis, and dilated cardiomyopathy (DCM). Although vaccination against CVB3 could significantly reduce the incidence of serious or fatal viral myocarditis and various other diseases associated with CVB3 infection, there is currently no vaccine or therapeutic reagent in clinical use. In this study, we contributed towards the development of a CVB3 vaccine by establishing an efficient and scalable ion exchange chromatography-based purification method for CVB3 virus and baculovirus-insect cell-expressed CVB3 virus-like particles (VLPs). This purification system is especially relevant for vaccine development and production on an industrial scale. The produced VLPs were characterized using a number of biophysical methods and exhibited excellent quality and high purity. Immunization of mice with VLPs elicited a strong immune response, demonstrating the excellent vaccine potential of these VLPs.
More Related Videos
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
05:03Author Spotlight: Elucidating the Pathways of TFH Cell Differentiation in Acute LCMV Challenges
Published on: April 26, 2024
